Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Bacil Pharma Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994
Last close ₹18.81up ₹0.41 (2.23%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
52-week range of traded prices to 30 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma shareholder meetings
67 filed, newest first. Page 1 of 2.
Sep 2026
23 Sep · Meeting
Aug 2026
Sep 2025
5 Sep · Meeting
5 Sep · Meeting
Nov 2024
14 Nov · Meeting
Oct 2024
Sep 2024
27 Sep · Meeting
4 Sep · Meeting
2 Sep · Meeting
2 Sep · Meeting
2 Sep · Meeting
Sep 2023
Aug 2023
24 Aug · Meeting
Sep 2022
1 Sep · Meeting
Sep 2021
Aug 2021
31 Aug · Meeting
31 Aug · Meeting
Oct 2020
Aug 2020
Oct 2019
Sep 2019
Aug 2019
Sep 2018
29 Sep · Meeting
29 Sep · Meeting
29 Sep · Meeting
29 Sep · Meeting
Aug 2018